Equity Overview
Price & Market Data
Price: $2.64
Daily Change: -$0.07 / 2.65%
Range: $2.46 - $2.70
Market Cap: $11,793,936
Volume: 20,693
Performance Metrics
1 Week: -11.71%
1 Month: 10.46%
3 Months: 22.79%
6 Months: -11.71%
1 Year: -49.43%
YTD: -13.44%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.